There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings in southern Africa where HIV-1 subtype C predominates. We report a patient infected with HIV-1 subtype C on DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations to four antiretroviral classes. There is need for drug resistance monitoring and clinical vigilance to ensure effectiveness of HIV treatment programs even in the era of DTG-based ART.
aBotswana Harvard AIDS Institute Partnership
bDepartment of Medical Laboratory Sciences, Faculty of Health Sciences
cDepartment of Medicine, Faculty of Medicine, University of Botswana
dMinistry of Health and Wellness, Gaborone, Botswana
eDepartment of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
fInfectious Disease Care Clinic, Princess Marina Hospital, Gaborone, Botswana
gDepartment of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
hCareena Centre for Health, Gaborone, Botswana.
Correspondence to Dr Kaelo K. Seatla, MBBS, DTMH, Botswana Harvard AIDS Institute Partnership, Private Bag BO320, Bontleng, Gaborone, Botswana. Tel: +267 390 2671; fax: +267 390 1284; e-mail: email@example.com, firstname.lastname@example.org
Received 15 April, 2018
Revised 7 May, 2018
Accepted 31 May, 2018